MOG (35-55): Gold-Standard Peptide for EAE and Multiple Sclerosis Models

Executive Summary: MOG (35-55) is a truncated peptide derived from human myelin oligodendrocyte glycoprotein, specifically amino acids 35 to 55, and is widely used to induce experimental autoimmune encephalomyelitis (EAE) in rodent models of multiple sclerosis (MS) (APExBIO). It elicits robust T and B cell immune responses, resulting in CNS demyelination and MS-like pathology in susceptible strains (Xu et al., 2025). MOG (35-55) enables mechanistic studies of neuroinflammation, particularly the interferon and STAT1/2 pathways. It is water-soluble at ≥32.25 mg/mL and DMSO-soluble at ≥86 mg/mL, but insoluble in ethanol, and is typically administered subcutaneously with complete Freund's adjuvant. Recent advances link its use to insight on PARP7-mediated STAT1/2 regulation in EAE attenuation (DOI), providing a platform for both disease modeling and therapeutic exploration.

Biological Rationale

MOG (35-55) is a synthetic peptide derived from the extracellular domain of human myelin oligodendrocyte glycoprotein (MOG), amino acids 35–55. MOG is a member of the immunoglobulin superfamily expressed on CNS oligodendrocytes and myelin sheaths. The MOG (35-55) region contains immunodominant T-cell epitopes recognized by murine MHC II molecules, making it uniquely effective in triggering CNS-directed autoimmunity in rodent models (APExBIO). Administration of this peptide, especially in combination with adjuvants such as complete Freund's adjuvant (CFA), reliably induces EAE—a well-validated animal model of relapsing-remitting multiple sclerosis. The utility of MOG (35-55) lies in its reproducible induction of demyelination, neuroinflammation, and motor deficits, which mirror MS pathology in humans (MOG (35-55) Peptide: Bridging Mechanistic Immunology). This article extends the latter by detailing current mechanistic insights into the peptide’s immune activation and solubility parameters. MOG (35-55) is essential for dissecting the interplay of adaptive immune cells and CNS antigens in neuroinflammatory disease.

Mechanism of Action of MOG (35-55)

MOG (35-55) functions as a potent autoantigen, driving T cell and B cell responses against myelin. Upon subcutaneous injection with CFA, antigen-presenting cells process and present the peptide via MHC II, activating encephalitogenic CD4+ T cells. These T cells migrate across the blood-brain barrier and orchestrate a cascade including cytokine secretion, B cell activation, and recruitment of effector cells, culminating in CNS demyelination. The peptide’s immunogenic sequence is optimal for murine strains (e.g., C57BL/6, HLA-DR2 transgenic), enabling reproducible disease induction. Mechanistically, MOG (35-55) administration increases NADPH oxidase activity and MMP-9 expression in vitro, implicating oxidative stress and matrix remodeling in EAE pathogenesis (Xu et al., 2025). The peptide helps elucidate regulatory pathways, such as PARP7-mediated STAT1/2 degradation, which modulate disease severity and are targets for emerging therapies (MOG (35-55) and the Future of Translational MS Research). This article updates the latter by presenting new evidence on dose-responsiveness and IFN-related mechanisms.

Evidence & Benchmarks

• MOG (35-55) (SKU A8306) induces EAE in C57BL/6 mice when administered subcutaneously at 50–150 μg per animal with CFA, producing a well-characterized relapsing-remitting neurological phenotype (Xu et al., 2025).
• MOG (35-55)-induced EAE recapitulates key features of MS, including extensive CNS demyelination and perivascular lymphocyte infiltration (Gold Standard Peptide for Experimental Autoimmune Encephalomyelitis).
• MOG (35-55) triggers dose-dependent increases in NADPH oxidase and MMP-9 activities in cultured immune cells, indicating heightened oxidative stress and extracellular matrix breakdown (Xu et al., 2025).
• PARP7 inhibition in MOG (35-55)-induced EAE stabilizes STAT1/STAT2 and attenuates disease severity, highlighting peptide utility in mechanistic and interventional research (Xu et al., 2025).
• MOG (35-55) is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO but is insoluble in ethanol; optimal stock preparation is 0.5 mg/mL in sterile water, with warming and sonication recommended (APExBIO).
• Stock solutions stored desiccated at -20°C and used promptly retain biological activity and minimize peptide degradation (Scenario-Guided Best Practices with MOG (35-55)).

Applications, Limits & Misconceptions

MOG (35-55) is primarily employed for:

• Inducing EAE as a preclinical model for relapsing-remitting MS, allowing the study of demyelination, immune infiltration, and neuroinflammation.
• Dissecting the role of type I interferon signaling and regulatory molecules such as PARP7 in neuroautoimmunity (Xu et al., 2025).
• Evaluating candidate immunomodulatory therapies in vivo in a reproducible disease context.
• Studying oxidative and proteolytic cascades relevant to CNS tissue remodeling.

However, limitations include species and strain specificity, as not all rodents are susceptible to MOG (35-55)-induced EAE. The peptide does not recapitulate all aspects of human MS, notably the heterogeneity in lesion distribution and chronicity. Additionally, over-reliance on a single disease model can obscure the diversity of autoimmune mechanisms in humans. For further mechanistic exploration, see MOG (35-55): Next-Gen Mechanistic Insights, which this article clarifies by providing explicit dose benchmarks and solubility data.

Common Pitfalls or Misconceptions

• MOG (35-55) does not reliably induce EAE in all mouse strains; optimal results are reported in C57BL/6 and HLA-DR2-transgenic mice.
• Peptide solubility is temperature- and solvent-dependent; ethanol is not suitable for dissolution.
• Storage at temperatures above -20°C or multiple freeze-thaw cycles can lead to peptide degradation and reduced activity.
• Immune responses are adjuvant-dependent; omission or substitution of CFA can result in suboptimal disease induction.
• MOG (35-55) models T cell-driven demyelination but may not capture all aspects of B cell pathology seen in human MS.

Workflow Integration & Parameters

For experimental use, it is recommended to prepare MOG (35-55) stock solutions at 0.50 mg/mL in sterile water. Warming and ultrasonic bath treatment enhance solubility. The peptide is stable when desiccated and stored at -20°C; stock solutions should be used promptly after reconstitution. For EAE induction, subcutaneous administration of 50–150 μg per mouse, emulsified in CFA, yields dose-dependent neurological deficits and weight loss. In vitro, MOG (35-55) can be used to stimulate lymphocytes, assess cytokine profiles, and measure oxidative or proteolytic activity (e.g., MMP-9 induction). Researchers should calibrate dosage and readouts according to strain, age, and sex of the animal model. For best practices in solubility and dosing, refer to Scenario-Guided Best Practices with MOG (35-55); this article extends guidance by mapping dose to mechanistic output (e.g., STAT1/2 stability).

When selecting reagents, sourcing from established suppliers such as APExBIO ensures batch consistency and documentation (the A8306 kit).

Conclusion & Outlook

MOG (35-55) remains the gold-standard peptide for modeling experimental autoimmune encephalomyelitis and relapsing-remitting MS in rodents. Its robust, reproducible induction of neuroinflammation and demyelination supports a wide range of mechanistic and preclinical studies. Integration with current mechanistic insights—such as the PARP7-STAT1/2 axis—enables researchers to test novel hypotheses and therapies. As the field advances, continued optimization of dosing, solubility, and immune readouts will further enhance the translational value of MOG (35-55)-based models. For detailed product specifications and ordering, see APExBIO’s MOG (35-55) page.